We are thrilled to announce our ground breaking Phase II results published in Addiction Journal (April 10th 2024) entitled:

Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial.

The article demonstrates the positive results of Kinnov Therapeutics phase II trial in the reduction of total alcohol consumption in patients with severe alcohol use disorder.

Addiction is the official and reference journal of the Society for the Study of Addiction, and has been in publication since 1884. It publishes peer-reviewed research reports on pharmalogical and behavioural addictions, bringing together research conducted within many different disciplines.

Our phase II results published in Addiction journal !